A New Era of Onshoring: Lillys Multi-Billion-Dollar Manufacturing Pivot In a striking departure from decades of industry practice, pharmaceutical giant Eli Lilly is executing a profoundly confident and expensive strategic realignment by committing over $50 billion over the past five years to expand
The journey from a promising chemical compound to a life-saving medicine on a pharmacy shelf is notoriously long, arduous, and astronomically expensive, often representing a decade-long gamble with billions of dollars at stake. This traditional "artisanal" approach to chemistry, reliant on manual
Picture a world where a single treatment could cure a life-threatening disease by rewriting the very code of a patient’s biology. Cell and gene therapies (CGT) are making this vision a reality, offering personalized solutions that repair or replace faulty cells and genetic material. These therapies
What if the next breakthrough in life-saving therapies was just a step away, waiting for the right tools and proximity to become reality? In a world where biopharmaceutical challenges grow more complex by the day, Thermo Fisher Scientific is stepping up with an ambitious expansion of bioprocess
What does it take for a pharmaceutical titan to pour $332 million into a new facility while staring down the barrel of regulatory scrutiny? Sun Pharma, India’s leading drugmaker, is capturing attention with a daring investment in Madhya Pradesh, India, even as it wrestles with significant
From Legacy Pills to Precision Platforms: Why Novartis Is Rewiring Its Factories Now A sprawling pivot only makes sense when the old playbook stops working and the new one promises faster launches, steadier supply, and tighter quality for therapies that cannot afford a slip. Manufacturing leaders
